Home › Macrophage Therapeutics Produces First Two Immunoconstructs
 

Keywords :   


Macrophage Therapeutics Produces First Two Immunoconstructs

2015-09-28 06:00:20| chemicalonline Home Page

Macrophage Therapeutics, Inc., a subsidiary of Navidea Biopharmaceuticals, Inc., recently announces that it has developed a process for producing the first two therapeutic Manocept immunoconstructs, MT-1001

Tags: produces therapeutics

Category:Chemicals

Latest from this category

All news
10.06Behr Announces First-Ever Commercial Color Forecast
10.06Evonik Strengthens Management Team in North America
10.06ROSS Mixers Offers Factory Restored Equipment
10.06BASF Researching CO2-neutral Production of Bio-based Fumarate Using Bacteria Found in Cow Stomachs
08.06Weekly Recap: H-I-S Paint, AkzoNobel, DuPont Top This Weeks Stories
07.06USGBC Applauds Final Definition of a Zero Emissions Building
07.06Nycote Laboratories Acquires New Californian HQ
07.06Nycote Laboratories Acquires New California HQ
Chemicals »
11.06Singapore Airlines offers to pay turbulence victims
11.06Mini China parts probe expanded by US Senate panel
11.06Eastern North Pacific Tropical Weather Outlook
11.06Atlantic Tropical Weather Outlook
11.06Why the EU might be about to make Chinese electric cars more expensive
10.06Apple brings ChatGPT to iPhones in AI overhaul
10.06Beyer joins K-State ASI Department as assistant professor of Sustainable Fresh Meat Industry
10.06Fed beef production steady; Non-fed beef production down in 2024
More »